| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | -97.1% | +318.1% |
| R&D Expense | $99.2M | -11.8% | +17.3% |
| SG&A Expense | $69.5M | +5.7% | +22.6% |
| Operating Income | -$166.8M | -49.5% | -18.4% |
| Interest Expense | $11.4M | +2.4% | +27.2% |
| Net Income | -$306.2M | -127.9% | -90.7% |
| EPS (Basic) | -$2.55 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $225.5M | +200.9% | +380.9% |
| Accounts Receivable | $1.8M | -78.5% | +641.0% |
| Current Assets | $977.3M | +10.2% | -4.0% |
| Total Assets | $1.44B | +17.2% | +0.0% |
| Current Liabilities | $142.1M | +8.5% | +29.4% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$367.4M | — | — |
| Capital Expenditures | $19.2M | — | — |
| Investing Cash Flow | $87.9M | — | — |
| Financing Cash Flow | $413.8M | — | — |
| Free Cash Flow | -$386.5M | — | — |
| -127.7% |
| -87.5% |
| EPS (Diluted) | -$2.55 | -127.7% | -87.5% |
| $1.00B |
| +64.3% |
| +61.6% |
| Total Liabilities | $1.96B | +22.8% | +35.0% |
| Stockholders' Equity | -$521.1M | -41.3% | -3646.1% |